Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
The new site enables end-to-end production of viral vector gene therapies
Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
Subscribe To Our Newsletter & Stay Updated